Cardiac amyloidosis is not nearly as rare as one might think, and with effective treatments finally emerging in recent years, there's a need to increase awareness of the condition to allow for earlier diagnosis and better patient outcomes. So say the editors behind an amyloidosis-focused special issue of JACC: CardioOncology, published Tuesday, and other researchers in the field interviewed by TCTMD.
"The field of amyloidosis has really seen an explosion in growth, and I think a lot of that is secondary to advancements in science," said Bonnie Ky, MD (University of Pennsylvania, Philadelphia), editor-in-chief of the journal. She pointed to developments in diagnostic strategies-especially the use of noninvasive modalities rather than biopsy for identifying transthyretin (ATTR) amyloidosis-and "dramatic improvements in terms of treatment strategies that have really changed the game."